Patents by Inventor Joerg Lill

Joerg Lill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESS FOR THE PURIFICATION OF OLIGONUCLEOTIDES
    Publication number: 20210347800
    Abstract: The invention relates to a new process for the purification of oligonucleotides which comprises the removal of the acid labile 5?hydroxy protecting group at the 5?-O-oligonucleotide terminus of the oligonucleotide by way of tangential flow filtration with an acidic buffer solution. The process requires less steps and allows a higher degree of automation.
    Type: Application
    Filed: April 21, 2021
    Publication date: November 11, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg LILL, Filippo SLADOJEVICH
  • Process for GalNAc oligonucleotide conjugates
    Patent number: 11021503
    Abstract: The invention comprises a process for the preparation of therapeutically valuable GalNAc cluster oligonucleotide conjugates. The process comprises the coupling of an alkali metal salt, earth alkali metal salt or a tetraalkylammonium salt of an oligonucleotide with a GalNAc cluster compound or with a salt thereof and a subsequent purification.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: June 1, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Simon Breitler, Joerg Lill, Kurt Puentener, René Trussardi
  • Processes for the preparation of GalNAc acid derivatives
    Patent number: 10597417
    Abstract: The invention comprises a new process for the preparation of GalNAc derivatives of the formula I wherein n is an integer between 0 and 10 and its salts, corresponding enantiomers and/or optical isomers thereof. The GalNAc acid derivative of formula I can be used for the preparation of therapeutically valuable GalNAc oligonucleotide conjugates.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 24, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Joerg Lill, Rene Trussardi
  • PROCESS FOR GALNAC OLIGONUCLEOTIDE CONJUGATES
    Publication number: 20200079807
    Abstract: The invention comprises a process for the preparation of therapeutically valuable GalNAc cluster oligonucleotide conjugates. The process comprises the coupling of an alkali metal salt, earth alkali metal salt or a tetraalkylammonium salt of an oligonucleotide with a GalNAc cluster compound or with a salt thereof and a subsequent purification.
    Type: Application
    Filed: November 21, 2019
    Publication date: March 12, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Simon BREITLER, Joerg LILL, Kurt PUENTENER, René TRUSSARDI
  • PROCESSES FOR THE PREPARATION OF GALNAC ACID DERIVATIVES
    Publication number: 20180162894
    Abstract: The invention comprises a new process for the preparation of GalNAc derivatives of the formula I wherein n is an integer between 0 and 10 and its salts, corresponding enantiomers and/or optical isomers thereof. The GalNAc acid derivative of formula I can be used for the preparation of therapeutically valuable GalNAc oligonucleotide conjugates.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 14, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg Lill, Rene Trussardi
  • PURIFIED CARDIOGENIN ISOMER AND RELATED METHODS
    Publication number: 20160207869
    Abstract: A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ column. The purity of the isolated cardiogenin major isomer can be further increased by crystallization, yielding isolated cardiogenin major isomer having HPLC purity as high as 98.97% (a/a) at 210 nm and a potency of 95.50%) (w/w).
    Type: Application
    Filed: August 28, 2015
    Publication date: July 21, 2016
    Inventors: Andreas KYAS, Ernst FREUND, Oliver SCHLÖRKE, Joerg LILL, Lars ROGALL, Dario MENIA, Gary ELLIOTT, James PATERNITI
  • PURIFIED CARDIOGENIN ISOMER AND RELATED METHODS
    Publication number: 20130345159
    Abstract: A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ column. The purity of the isolated cardiogenin major isomer can be further increased by crystallization, yielding isolated cardiogenin major isomer having HPLC purity as high as 98.97% (a/a) at 210 nm and a potency of 95.50%) (w/w).
    Type: Application
    Filed: December 21, 2011
    Publication date: December 26, 2013
    Applicant: HUYA BIOSCIENCE INTERNATIONAL LLC
    Inventors: Andreas Kyas, Ernst Freund, Oliver Schlörke, Joerg Lill, Lars Rogall, Dario Menia, Gary Elliott, James Paterniti